RecruitingPhase 1Phase 2NCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470


Sponsor

Bristol-Myers Squibb

Enrollment

224 participants

Start Date

Jul 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986470, a drug called Famotidine, and others for people with anemia, sickle cell and healthy volunteers. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986470

Specified dose on specified days

DRUGPlacebo

Specified dose on specified days

DRUGFamotidine

Specified dose on specified days

DRUGPantoprazole

Specified dose on specified days


Locations(33)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of California San Diego - La Jolla

La Jolla, California, United States

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States

Yale-New Haven Hospital

New Haven, Connecticut, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Local Institution - 0034

Chicago, Illinois, United States

Local Institution - 0001

Lenexa, Kansas, United States

Local Institution - 0064

Baltimore, Maryland, United States

Local Institution - 0024

Boston, Massachusetts, United States

Boston Medical Center

Boston, Massachusetts, United States

Local Institution - 0030

St Louis, Missouri, United States

Local Institution - 0033

Greenville, North Carolina, United States

Local Institution - 0028

Cleveland, Ohio, United States

Local Institution - 0029

Philadelphia, Pennsylvania, United States

Thomas Jefferson University - Medicine/GI and Hepatology

Philadelphia, Pennsylvania, United States

Local Institution - 0032

Pittsburgh, Pennsylvania, United States

Local Institution - 0027

Greenville, South Carolina, United States

Inova Schar Cancer Institute

Fairfax, Virginia, United States

Virginia Commonwealth University (VCU) Medical Center

Richmond, Virginia, United States

Local Institution - 0050

Vancouver, British Columbia, Canada

Local Institution - 0051

Toronto, Ontario, Canada

Local Institution - 0061

Créteil, France

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille, France

Hôpital Universitaire Necker Enfants Malades

Paris, France

CHU Strasbourg-Hautepierre

Strasbourg, France

Local Institution - 0011

Milan, Lombardy, Italy

Local Institution - 0037

Padua, Italy

Local Institution - 0009

Verona, Italy

University Hospitals Sussex NHS Foundation Trust

East Sussex, Brighton And Hove, United Kingdom

Local Institution - 0044

London, Greater London, United Kingdom

King's College Hospital

London, London, City of, United Kingdom

Local Institution - 0005

Leeds, United Kingdom

Local Institution - 0047

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06481306


Related Trials